Xinhuanet Jiangsu Channel and Jiangsu Food and Drug Administration jointly launched the "Food and Drug Safety Reporters" campaign to gain insights into pharmaceutical companies, and released a report on Hansoh Pharma's new drug R&D, quality management system and integrity building.
Link to the campaign: http://www.js.xinhuanet.com/2014zt/cxyq.htm
Link to the report: http://www.js.xinhuanet.com/2014-11/11/c_1113202692.htm
Original text:
Integrity and Innovation Make Hansoh Pharma a Great Brand
Strict quality management, corporate principle of integrity, and innovation in new drug R&D are the contributors to Hansoh Pharma's success. Jiangsu Hansoh Pharma Group is a modern pharmaceutical company established in 1995, and after 19 years of development, has now become a modern and innovative pharmaceutical industry group integrating chemical and biological drug research, API synthesis, preparation production and product sales, ranked among top 20 in the Top 100 Ranking of China's Pharmaceutical Industry 2013, and securing an important market share in the six pharmaceutical fields of anti-tumor, psychiatric, endocrine, gastrointestinal, antibiotic and cardiovascular.
Wu Yulan, Vice President of Hansoh Pharma in charge of product quality, said that the company has been improving its quality control system, and the quality of all products has reached and in some cases even exceeded the international level. In 2013, all workshops and dosage forms of Hansoh Pharma passed the new GMP certification two years earlier than as required by the state. A number of its first generic and fine generic drugs have outperformed the original drugs in domestic sales and received wide recognition from the domestic market, which is undoubtedly an important result of Hansoh's unremitting pursuit of excellent quality over years. China Quality Association for Pharmaceuticals has awarded Hansoh Pharma the title of "Quality Integrity Demonstration Enterprise in China's Pharmaceutical Industry" for many times in a row, and has become an important witness to Hansoh Pharma 's quality control efforts.
High-quality products bring Hansoh Pharma an increasingly solid product reputation; Hansoh Pharma also knows better in the market competition that quality is an important guarantee for the survival of a company, the loss of which will make it difficult to re-establish market confidence. Therefore, Hansoh Pharma is now implementing the quality management policy of "all staff, whole process and continuous improvement" even more strictly to ensure its lasting brand strength.
Hansoh Pharma takes "integrity basis and continuous improvement" as its quality philosophy. From feedstock input to intermediates to product output, Hansoh Pharma has set up a strict and meticulous quality assurance and document management system to ensure that "no feedstocks below internal control standards enter, no intermediates below internal control standards flow into the next process, and no products below internal control standards leave". It is indeed such high standard and high requirement that make Hansoh's continuous success in quality management.
"Although this has led to increased costs and reduced benefits to some extent, we've gained more than market shares in the long run. In China's pharmaceutical market, Hansoh Pharma has become a synonym of quality. Brand building has brought great returns to Hansoh Pharma. In the psychiatric field, Hansoh Pharma secures the largest market share in the domestic market; and in the anti-tumor field, Hansoh Pharma is firmly among the top five." The head of sales of Hansoh remarked, "Whether in terms of quality management or new drug R&D, high standards are always an important element to help us build great brands."
"Staying concentrated, focused and professional to become the leader of innovative drugs in China" is Hansoh Pharma's corporate vision. Hansoh Pharma is working hard to build itself into a technology leader. Through years of continuous efforts, Hansoh Pharma has proved its leading position with actual scientific achievements: In May 2014, Hansoh Pharma 's first national Class 1.1 new drug, Mailingda (generic name: morinidazole and sodium chloride injection), was officially launched. As we can see from the official website of China Food and Drug Administration, Class 1.1 new drugs are "APIs and their preparations made by synthetic or semi-synthetic method" with completely independent intellectual property rights, which means that Hansoh Pharma has the first completely independently developed drug. Hansoh Pharma also has nearly 20 Class 1.1 new drugs at different clinical stages. This means that even uncertainty is taken into consideration, Hansoh Pharma will have 10+ national Class 1.1 new drugs ready to be marketed in the future.
At the modern research institute of nearly 35,000m2, hundreds of precision drug analysis instruments are in operation. Hansoh Pharma has successively undertaken more than 40 scientific and technological projects of the National Development and Reform Commission, the Ministry of Industry and Information Technology, and the Ministry of Science and Technology, including more than 20 National Major Scientific and Technological Special Projects of "Significant New Drugs Development". "Zefei" (generic name: gemcitabine hydrochloride for injection), the flagship product for the treatment of advanced non-small cell lung cancer, won China Patent Gold Award 2014 and the second prize of National Science and Technology Progress Award 2014; "Oulanning" (generic name: olanzapine tablets), the flagship product for the treatment of schizophrenia and depression, won the second prize of National Science and Technology Progress Award 2014.
According to the management of Hansoh Pharma, "technology" is the core competitiveness of a pharmaceutical company now and also in the future, and only with the innovative spirit of continuous development and pursuit of excellence, can a pharmaceutical company secure a favorable position in the cruel market competition like a battlefield. Therefore, no matter in the warning signs all over Hansoh's workplace, in the heated debates among employees, or throughout the work, "innovation" is unsurprisingly the highlight. Hansoh Pharma 's innovation has gone far beyond the scope of scientific and technological innovation, and has undoubtedly been integrated in its administrative management, production management and sales management. Innovation is the essence of Hansoh Pharma 's culture. Its important position in Hansoh Pharma 's business management and development process can be traced in the company's corporate spirit: "Great in Ambition, Strategic in Vision, Meticulous in Management, and Active in Innovation".
